The abstract is read at the publisher; the summary is JClub's.
NEK8 is significantly upregulated in cisplatin-resistant bladder cancer and is linked to unfavorable prognosis, promoting cisplatin resistance and tumor progression in vitro and in vivo.
- Why it matters: Cisplatin resistance limits the effectiveness of standard chemotherapy for advanced bladder cancer, but the molecular pathway driving resistance is not well defined.
- What they did: The study tested NEK8 function in bladder cancer models and found NEK8 interacts with ALYREF, promoting ALYREF phosphorylation and nuclear translocation; nuclear ALYREF binds m5C-modified CDK18 mRNA to stabilize it.
- The result: Increased CDK18 expression supports DNA damage repair, which is associated with cisplatin resistance in bladder cancer, identifying a NEK8–ALYREF–CDK18 axis as a mechanistic driver.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.